FDA approves new treatment for carcinoid syndrome

On Feb. 28, the U.S. Food and Drug Administration (FDA) approved Xermelo (telotristat ethyl) tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone has inadequately controlled. Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here